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Jean-François Jusot1*, Zilahatou Tohon2, Abdoul Aziz Yazi3 and Jean-Marc Collard4Abstract
Background: Beside high mortality, acute bacterial meningitis may lead to a high frequency of neuropsychological
sequelae. The Sahelian countries belonging to the meningitis belt experience approximately 50% of the meningitis
cases occurring in the world. Studies in Africa have shown that N. meningitidis could cause hearing loss in up to
30% of the cases, exceeding sometimes measles. The situation is similar in Niger which experiences yearly
meningitis epidemics and where rehabilitation wards are rare and hearing aids remain unaffordable. The aim of this
study was to estimate the frequency of neuropsychological sequelae after acute bacterial meningitis in four of the
eight regions of Niger.
Methods: Subjects exposed to acute bacterial meningitis were enrolled into a cohort with non exposed subjects
matched on age and gender. Consenting subjects were interviewed during inclusion and at a control visit two
months later. If clinical symptoms or psychological troubles persisted at both visits among the exposed subjects
with a frequency significantly greater than that observed among the non exposed subjects, a sequelae was
retained. The comparison of the frequency of sequelae between non exposed and exposed subjects to bacterial
meningitis was also calculated using the Fisher exact test.
Results: Three persisting functional symptoms were registered: headaches, asthenia, and vertigo among 31.3, 36.9,
and 22.4% respectively of the exposed subjects. A significant motor impairment was retrieved among 12.3% of the
exposed versus 1.6% of the non exposed subjects. Hearing loss significantly disabled 31.3% of the exposed subjects
and 10.4% exhibited a serious deafness.
Conclusions: This study carried out in Niger confirms two serious neurological sequelae occurring at high
frequencies after bacterial meningitis: severe and profound hearing loss and motor impairment. Cochlear
implantation and hearing aids are too expensive for populations living in developing countries. Neurological
sequelae occurring after meningitis should sensitize African public health authorities on the development of
rehabilitation centers. All these challenges can be met through existing strategies and guidelines.
Keywords: Meningococcal, Complications, Disability, Less-developed countriesBackground
Beside high mortality, acute bacterial meningitis may lead
to a high frequency of neuropsychological sequelae in 3 to
47% of cases, causing 160,000 yearly disabilities worldwide
[1-5]. Among the three main microorganisms causing acute
bacterial meningitis, Streptococcus pneumoniae (Sp) is the
most lethal and most disabling followed by Haemophilus
influenzae (Hi) and Neisseria meningitidis (Nm) [6].* Correspondence: jfjusot@gmail.com
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reproduction in any medium, provided the orThe Sahelian countries belonging to the meningitis belt
experience approximately 50% of meningitis cases for a
population at risk with an estimated 350 million inhabi-
tants. Indeed, epidemics occur every year with major epi-
demics every 5 – 12 years with high attack rates. Attack
rates are high ranging from 100 to 800 per 100,000. Since
the first cerebrospinal meningitis outbreak occurred in
Nigeria in 1905, other epidemics have threatened the
meningitis belt [7]. In 1996, large outbreaks spread across
the meningitis belt leading to 250,000 suspected cases
and 25,000 deaths [8]. They were mainly due to N.
meningitidis serogroup A. In 2002 a large outbreak duetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in 2009, 80,000 cases and more than 4,000 deaths
occurred in this part of Africa [10]. Niger experienced
large outbreaks in 2000, 2003 and 2009, in which N.
meningitidis serogroup A was the main causative agent.
Although a polysaccharide vaccine (A, C, W, Y serogroups
of N. meningitidis) was widely used in mass vaccination
campaigns to control transmission of the disease, a new
conjugate vaccine against serogroup A was introduced in
2010. Other emerging serogroups of N. meningitidis, such
as W135 and X, have been incriminated in recent out-
breaks [11,12].
In the perspective of physical rehabilitation, the most
serious sequelae after acute bacterial meningitis are
neurological including motor impairment, epilepsy,
cecity or vision loss, speech disorder and hearing loss. In
Africa, studies of bacterial meningitis sequelae have been
mainly conducted more within hospital wards than in
peripheral and remote health care centres usually lo-
cated far from reference hospitals. The majority of the
studies on post-meningitis sequelae therefore consider
in-hospital outcomes whereas post-discharge outcomes
are less frequently reported [4].
Hearing loss could result in irreversible neurological
sequelae, frequently severe or profound, probably due to
a serious or suppurative labyrinthitis occurring very early
during the acute phase of meningitis and evolving to-
wards a labyrinthitis ossificans [13,14]. The frequency of
hearing loss exhibits large variations, between 2 and 48%
depending on the studies [4]. Pneumococci have been
documented as the major cause of severe/profound
hearing loss leading to the majority of cochlear implan-
tations [15]. Nevertheless, studies in Africa have shown
that N. meningitidis could be the cause in 30% of hear-
ing loss, sometimes exceeding measles [16-18]. The situ-
ation is similar in Niger which experiences yearly
meningitis epidemics and yet where rehabilitation wards
are rare and hearing aids remain unaffordable and too
expensive for the disabled. In addition, frequency of
sequelae after bacterial meningitis has not yet been
rigorously determined in the country. Consequently, it is
difficult to estimate the need for rehabilitation and
sensitization for health authorities without rigorous data
for decision making.
The aim of this study was therefore to estimate the
frequency of the sequelae after acute bacterial meningitis
in four of the eight regions of Niger.
Methods
Study population
The study population concerned inhabitants of four of the
eight regions of Niger: the capital city Niamey, Dosso,
Tillabery, and Maradi. These four regions comprised 9
million among the 15 million inhabitants of Niger in 2011.From 27/12/2010 - 13/05/2011, 252 cases could be
potentially enrolled in the regions targeted by this study,
representing 87.3% due to N. meningitidis of W
serogroup and 11.5% of S. pneumoniae.
Study design
The study design consisted of an exposed/non exposed
cohort. Eligible subjects were retrieved after study inter-
viewers inquired from the district health authorities if
suspected meningitis cases had been notified. Identified
subjects were considered exposed if one of the three
main causal agents, N. meningitidis, S. pneumoniae or
H. influenzae, was identified in their cerebral spinal fluid
(CSF) by PCR or latex test performed as part of the rou-
tine microbiological surveillance coordinated by the
CERMES. Non exposed subjects did not have any men-
ingitis or meningeal syndrome according to the WHO
suspected case classification [19]. They were selected
from the family of their corresponding exposed subject
and matched on gender and age. Subjects known to have
suffered from a similar pathology as the post-meningitis
sequelae were excluded. All the subjects were enrolled if
they were 5 years old and above to facilitate the clinical
and audiometric examination.
Studied factors
After enrolment, all the exposed and non exposed sub-
jects were interviewed by two physicians, one located at
Niamey and the other at Maradi. Both physicians were
readily available to perform an immediate visit when a
case was suspected or diagnosed in a health care facility.
They were therefore aware of the infectious status of the
subjects visited at the health care facility during their
acute clinical phase for the exposed subjects. Non ex-
posed subjects were visited at home. The two physicians
were general practitioners trained on the aims of the
study and the tools to be used (protocol, operational
guide, questionnaires, audiogram, consent form). They
performed a complete and in-depth clinical examination,
especially focused on seeking neurological, sensitive,
sensorial, and motor impairments. Clinical and psycho-
logical examinations as well as audiograms (Amplitude®
T-Series audiometer) were performed both at the inclu-
sion visit and during the control visit performed
2 months later. This duration of follow-up was validated
by the scientific committee of the study due to the diffi-
culties to retrieve subjects living in remote and difficult-
to-access areas.
For the audiology study, the audiograms were
interpreted by two physicians specialised in otorhino-
laryngology who were blinded to the exposed or non ex-
posed status of the subjects. The hearing losses were
classified according to the classification of the Bureau
International d’Audiophonologie. Deafness was mild,
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were from 21 to 40 dB, 41to 70 dB, 71 to 90 dB, and
>90 dB respectively. Severe and profound hearing losses
were regrouped under serious hearing loss. Air and bone
conduction was also assessed to identify the type of
hearing loss.
Psychological behaviour was assessed by two psychol-
ogists during the visits with the physicians. The two
psychologists belong to the technicians’ category of the
civil service in Niger. The following items extracted
from the Conners’questionnaire were explored: blue
mood, decreased energy, decreased of pep, poor motiv-
ation, serious asthenia, irritability, scared without any
reason, sleeping difficulties, difficulty concentrating,
nervousness, crying without any reason, and difficulty
in daily living activities.
If the clinical symptoms or psychological disorders
persisted at the control visit among the exposed subjects
with frequencies significantly greater than those ob-
served among the non-exposed subjects, a sequelae was
retained. The audiogram result for the most altered ear
at the control visit was retained to qualify the level and
type of hearing loss [20].
All the findings were recorded in a questionnaire. All
the questions were asked in the local language when
necessary.Statistical analysis
The statistical analysis estimated the frequency of the
symptoms at inclusion between exposed and non-exposed
subjects. The comparison was made using the Fisher exact
test. In order to show a trend in the severity of hearing
loss associated to bacterial meningitis, a trend test of
Cochran-Armitrage was used. These two tests were
performed using the software Winpepi [21].
A score for behavioural troubles was built and vali-
dated by estimating the reliability of 12 psychological
items using the packages ltm and CMC of R software to
estimate Cronbach alpha coefficient [22]. The presence
of an item accounted for 1 point versus 0 in its absence.
The score was calculated by summing the points with
the retained items.
The comparison of the frequency of the sequelae be-
tween exposed and non exposed subjects was also calcu-
lated using the Fisher exact test. All the frequencies
were estimated with a 95% confidence interval.Ethical considerations
Study information was provided to the subjects or to
their family. Written informed consent was obtained
before inclusion. The study protocol was approved by
the National Ethics Committee of Niger (authorisation
N°014//2009/CCNE).Results
Characteristics of the subjects included
Among the 184 subjects who met enrolment criteria,
104 suspected as clinical acute bacterial meningitis were
visited and 83 were confirmed as exposed following
biological confirmation of acute bacterial meningitis.
Seventy nine non exposed subjects were included after
one died. During the follow-up, 3 exposed subjects died
(case fatality rate = 4.3%), and 13 exposed (15.7%) and 14
non exposed (17.7%) subjects were lost to follow-up two
months after the inclusion visit. Finally, 67 exposed and
65 non exposed subjects were retained for the analysis
to estimate the frequency of the sequelae. (Figure 1) The
subjects were visited 87 days (range = 50 – 141 days) on
average after their inclusion visit.Symptoms associated with meningitis
At inclusion, the 162 subjects recruited in the study
consisted of 83 meningitis cases and 79 non exposed sub-
jects. There was no gender predominance in the two
groups. The mean age was 13.5 years (SD = 8.9 y, range =
5 – 60 years) without any difference between meningitis
cases and non exposed subjects. The most frequent age
groups were 5 – 14 years and 15 – 24 years with respect-
ively 69.8% and 22.2% of the subjects. The predominant
causal agent was N. meningitidis W in 86.7% of the
meningitis cases; 6% were due to S. pneumoniae, 6% to
N. meningitidis serogroup A and 1.2% to serogroup C
(Table 1).
The main symptoms associated with meningitis are
depicted in Table 2 and comprised functional symptoms
like headache, asthenia, and insomnia in at least 50% of
the exposed subjects. Motor impairment for tonus and
walking was significantly found among 78.8% of the
exposed subjects in contrast to 5.1% of non exposed
subjects. Odour perception for soumbala, a well known
traditional spice, was altered for 45.4% of bacterial men-
ingitis cases. Facial muscles, bladder and anal sphincter
were also impaired in respectively 17.5, 31.3 and 43.8%
of the bacterial meningitis cases. No cecity was encoun-
tered, but the mean of visual acuity among meningitis
cases was lower than for the non exposed subjects with re-
spectively 8.8 and 9.3 (t test = −2.33, df = 128.2, p = 0.02).
Only bone conduction or both bone and air conduc-
tions and serious hearing losses were predominant
during acute bacterial meningitis, with OR = 4.84 and
13.1 respectively.
Four items were validated with the Cronbach alpha
coefficient (alpha = 0,847; 95% CI = 0,793 – 0,886): blue
mood, decreased energy, decreased of pep and severe
asthenia. The exposed subjects had a score of 2.6, sig-
nificantly greater than 0.8 in the non exposed subjects
(t test = 8.24, df = 147.7, p < 0.0001).
Figure 1 Flow chart explaining the distribution of the subjects during follow-up and according to their status.
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Among the 132 subjects remaining at the end of follow-
up, there was no gender predominance with a sex ratio
M:F = 0.94. The mean age was 12.8 years (SD = 8.1 years,
range = 5 – 55 years), 13 and 12.6 years respectively for
exposed and non exposed subjects.
Three functional symptoms persisted: headaches, as-
thenia, and vertigo among respectively 31.3, 36.9, and
22.4% of the exposed subjects with a significant risk of
persistence.
The risk of motor impairment reached 7.8 among the
subjects exposed to meningitis compared to the non ex-
posed subjects. A motor impairment was significantly
retrieved among 12.3% of the exposed versus 1.6% of the
non exposed subjects. Hearing loss disabled 31.3% of the
exposed subjects and 10.4% exhibited a serious deafness
with a significant risk of 7.1. When combining motor
impairment and hearing loss, the risk of neurological se-
quelae was 1.8 for exposed subjects versus non exposed
subjects (Table 3).Table 1 Basic parameters on the included subjects
Parameter Exposed Non exposed
n = 83 n = 79
Age: mean (SD) 13.7 (10.1) 13.2 (7.55)
Sex:
- Male: n (%) 44 (53.0) 38 (48.1)
Etiological agent by PCR or Latex:
- N. meningitidis: n (%) 78 (94) 0
Serogroup W135 72 (86.7) 0
Location:
- Niamey: n (%) 53 (63.9) 52 (65.8)No behavioural troubles persisted as the score was
similar among the exposed and non exposed subjects,
0.9 versus 0.5 (t test = 1.75, df = 125.6, p = 0.08).
Discussion
Three types of sequelae were observed in this study:
functional symptoms, hearing loss, and motor impair-
ment. We did not however address mental retardation
due to the lack of standard intelligence scoring tests
adapted to a country with low literacy rates. Functional
symptoms like headaches and asthenia were observed at
frequencies of 31.3 and 36.9%. An alteration of the VIIIth
pair of cranial nerve with vertigo, at least moderate and
serious hearing loss was developed respectively by 22.4,
19.4 and 10.4% of the exposed subjects. Finally, motor
impairment was observed among 12.3% of exposed sub-
jects. The frequencies of these sequelae are among the
highest values retrieved in studies performed in Africa
[4]. Generally, the frequency of sequelae increases with
the severity of the clinical form that is usually found
among pneumococcus cases. As N. meningitidis W was
the major causal agent in our study, it raises a question
on the severity linked to this serogroup which had a case
fatality ratio of 12% estimated in a study performed be-
tween 2003 and 2006 in Niger [11]. Another possible ex-
planation for the high frequencies of sequelae observed
in our study is the short duration of the follow-up, three
months in average, which could lead to an over estima-
tion because some sequelae could spontaneously regress
after this delay. However, increasing the study duration
could lead to a higher proportion of subjects lost to
follow-up and introduce a strong bias in the estimation
of frequencies and risks. Nevertheless, the Société de
Pathologie Infectieuse de Langue Française recommends
to perform an audiogram and a neurological examin-
ation one month after acute meningitis infection,
Table 2 Symptoms associated with meningitis at the inclusion
Symptoms Exposed Non exposed OR 95% CI p
n = 83 % n = 79 % Crude Lower Upper
Headaches 79 59.5 79 29.1 3.6 1.8 7.1 0.0002
Insomnia 80 58.8 79 22.8 4.8 2.3 10.2 <0.0001
Convulsions before admission 80 83.8 78 5.1 90.9 27.8 400 <0.0001
Asthenia 79 78.5 79 38.0 5.9 2.8 12.8 <0.0001
Sensation to pain and to touch perturbed 80 13.8 78 0 NC 2.7 NC 0.0007
At least one troubled reflex 80 62.5 78 15.4 9.0 4.1 21.3 <0.0001
Walking or tonus impaired 80 78.8 79 5.1 66.7 20.8 286 <0.0001
Odor of soumbala non recognised 77 45.4 77 22.1 2.9 1.4 6.3 0.004
Masseter motility impaired 80 21.3 78 0 NC 4.8 NC <0.0001
Facial motility impaired 80 17.5 77 3.9 5.2 1.4 29.4 0.009
Trouble in the voice 80 32.5 76 1.3 35.7 5.5 1493 <0.0001
Vertigo 79 55.7 79 15.2 6.9 3.1 16.4 <0.0001
Hearing loss type 76 79 0.0002
- No 27 35.5 53 67.1 1
- Air conduction altered 12 15.8 11 13.9 2.14 0.8 6.1 0.14
- Bone conduction altered or mixed 37 48.7 15 19.0 4.84 2.1 11.2 <0.0001
Hearing loss level 78 79 <0.0001
- No 27 34.6 53 67.1 1
- Mild 20 25.65 15 19.0 2.62 1.1 6.4 0.024
- Moderate 11 14.1 8 10.1 2.70 0.9 8.7 0.067
- Serious 20 25.65 3 3.8 13.1 3.4 72.9 <0.0001
Urgent miction 80 31.3 78 14.1 2.78 1.2 6.8 0.01
Trouble in defecation † 80 43.8 78 14.1 4.8 2.1 11.4 <0.0001
† These were constipation, faecal incontinence, faecal emergencies, and no control of the anal sphincter.
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three months during one year [23].
The frequency of severe/profound hearing loss was
10.4% compared to 1.6% in a study performed in Ghana
[2]. A high frequency of severe/profound hearing loss
was found in a study performed in Malawi among
hospitalised subjects [24]. Variations in frequencies ob-
served in the different studies could be related to the se-
verity of the meningitis since a severe illness could
exhibit a higher risk of sequelae [25].
Persistent headaches were declared more than one
week after CSF was taken and were therefore not linked
to the lumbar puncture [26,27]. This symptom was usu-
ally found at a similar frequency in the national surveil-
lance system of Sweden [28]. At the end of follow-up,
exposed subjects had a significantly higher spontaneous
declaration of headaches (27.9%) and psychological trou-
bles (16.2%) than non exposed subjects (21.5% and 3.1%
respectively, data not shown). This result should incite a
better assessment of functional symptoms like headaches
by investigating the type, intensity, irradiation, enhan-
cing or calming factors, and familial predisposition.Although they were declared significantly more by the
exposed subjects, psychological troubles were not con-
sidered as sequelae after assessment by the psychologists
even though they were frequent at the inclusion, as
shown using a reliable and validated score (Cronbach
alpha coefficient > 0.8). These results are in accordance
with Sumpter et al. (2011) who concluded that psycho-
logical consequences are due to sequelae after meningitis
and not directly due to meningitis [29].
An important asthenia persisted among 36.9% of the
exposed subjects, a frequency close to the 40.1% ob-
served in a study performed in Ghana [2]. This symptom
seems to be of important interest as it is frequently
found and was retained in the score, though not more
frequently declared spontaneously by the exposed sub-
jects compared to the non exposed subjects (data not
shown). These discordant observations should orientate
researchers’ attention to the assessment of subjective
psychological troubles to be probably explored more ad-
equately using qualitative study designs [30].
One of the limits of this study could be its power
which restricted the identification of other sequelae such
Table 3 Frequency and risk of sequelae after being exposed to an acute bacterial meningitis episode
Sequelae Exposed Non exposed p Crude RR 95% CI RR
n = 67 % n = 65 %
Functional symptoms
Headache 67 31.3 65 13.8 0.022 2.3 1.1 4.6
Asthenia 65 36.9 63 12.7 0.002 2.9 1.4 6.0
Vertigo 67 22.4 65 7.7 0.027 2.9 1.1 7.6
Hearing loss assessment1
Bone conduction altered or mixed 64 7.8 65 7.7 1 1.2 0.4 3.8
All levels of hearing loss 67 65
- No 46 68.7 53 81.5
- Mild 8 11.9 8 12.3 0.8 1.1 0.5 2.8
- Moderate 6 9.0 3 4.6 0.31 2.2 0.6 8.2
- Serious 7 10.4 1 1.5 0.031 7.1 0.9 56.0
- Moderate/serious 13 19.4 4 6.2 0.034 3.1 1.1 9.1
Motor impairment2 65 12.3 64 1.6 0.033 7.8 1 60.2
Neurological3 66 36.4 64 20.3 0.053 1.79 1.0 3.2
1 The most affected ear was retained.
2 Concerning walking and tonus.
3 Hearing loss or motor impairment.
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studies [4,26]. Epilepsy could occur after several years of
evolution whereas our study had only three months of
follow-up [31]. This duration of follow-up was chosen
according to the protocol study validated by the scien-
tific committee of the study and due to difficulties en-
countered on the field such as health care accessibility
which could inflate the percentage of participants lost to
follow-up. In addition, it was difficult to collect clinical
data relative to treatment because health care centres in
Niger were insufficiently or not inconsistently supplied
with antiepileptic drugs or corticoids; these drugs could
play a role in the occurrence of sequelae after meningi-
tis. Acute neurological signs like hydrocephalus were
investigated, but none was observed. Another limit was
the number of subjects lost during follow-up that could
introduce a non differential bias of classification and
overestimate the relative risks. A subject loss to follow-
up of more than 15% was observed and could be
explained by subjects living in remote areas with no
means to come to appointments for follow-up. After tak-
ing into account lost subjects by supposing they were
finally found disabled at the control visit, meningitis
remained a significant risk factor only for asthenia (data
not shown).
The high mortality rates due to bacterial meningitis in
Niger have enhanced the surveillance and control strat-
egies based on the implementation of reactive vaccin-
ation campaigns and early antibiotherapy. Recently, the
introduction of a conjugate vaccine increased the hopeof eradicating meningococci of serogroup A, one of the
major causes of large epidemics in the meningitis belt.
Nevertheless, pneumococci and meningococci of other
serogroups (i.e.: X and W) still threaten the populations
of the meningitis belt. This study carried out in Niger
confirms two serious neurological sequelae occurring
after meningitis: high frequencies of severe and pro-
found hearing loss, and motor impairment. Ideal follow-
up of patients requires the most modern radiographic
imageries, not affordable by Niger, for the timely detec-
tion of labyrinthitis ossificans [32]. Cochlear implant-
ation is indicated in the first two weeks of meningitis in
case of deafness [33]. Again, this treatment is not afford-
able to Niger’s populations. Similarly, hearing aids cost
20 times higher in developing countries than when pur-
chased elsewhere [34].Conclusions
Neurological sequelae, particularly severe hearing loss and
motor impairment, occurring after bacterial meningitis in
Niger should sensitize African public health authorities
towards early and rapid patient management accompanied
by the development of appropriate rehabilitation measures
through existing strategies and guidelines to manage hear-
ing loss [35,36]. Continuously implementing and improv-
ing early vaccination campaigns to prevent outbreaks
remains a big challenge and a way to prevent sequelae
especially with the emergence of W in Niger and other
Sahelian countries, since 2010.
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